In Silico Repurposing of FDA-Approved Drugs Targeting the RNA-Dependent RNA Polymerase (NS5B) of Hepatitis C Virus
Keywords:
Hepatitis C virus, NS5B, Molecular docking, Eltrombopag, ADMETAbstract
Hepatitis C virus (HCV) is a significant global health issue and is a common cause of chronic hepatitis, cirrhosis of the liver, and hepatocellular carcinoma (HCC). While direct-acting antivirals have made a significant impact on treatment success, the potential for drug resistance, high treatment costs, and limited access to treatment in many regions has sustained the need to explore therapeutic options. Drug repurposing provides a rapid and cost-effective approach to discovering new antiviral agents from approved compounds. The RNA-dependent RNA polymerase (NS5B) of HCV was chosen as the therapeutic target of this study because of its role in HCV viral RNA replication. A total of 2,134 FDA-approved drugs were obtained from DrugBank, and ZINC15 were subjected to structure-based virtual screening. Molecular docking was performed using AutoDock Vina. Eltrombopag and Nilotinib were identified as the top-ranked compounds with the highest binding affinities of -9.5 and -9.3 kcal/mol, respectively. Eltrombopag shows a higher binding affinity than the reference inhibitor, Dasabuvir. The interaction analysis showed that there were stable hydrogen bonds and hydrophobic interactions within the binding pocket. Eltrombopag was predicted to have favourable pharmacokinetic characteristics and no major toxicity concerns based on ADMET predictions. The binding region was also found to be less flexible, with the stable association of the Eltrombopag–NS5B complex during the entire simulation time period confirmed by MD simulation. These results indicate that Eltrombopag is a potential antiviral repositioning candidate against HCV that needs to be further validated in experiments.